HK1206608A1 - 三唑並化合物 - Google Patents

三唑並化合物

Info

Publication number
HK1206608A1
HK1206608A1 HK15107168.4A HK15107168A HK1206608A1 HK 1206608 A1 HK1206608 A1 HK 1206608A1 HK 15107168 A HK15107168 A HK 15107168A HK 1206608 A1 HK1206608 A1 HK 1206608A1
Authority
HK
Hong Kong
Prior art keywords
medication
dispenser
Prior art date
Application number
HK15107168.4A
Other languages
English (en)
Inventor
亞歷山大‧弗洛爾
卡特里‧格勒布科茨賓登
克里斯蒂安‧勒納
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1206608A1 publication Critical patent/HK1206608A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15107168.4A 2012-11-07 2015-07-27 三唑並化合物 HK1206608A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12191607 2012-11-07
PCT/EP2013/072966 WO2014072261A1 (en) 2012-11-07 2013-11-04 Triazolo compounds

Publications (1)

Publication Number Publication Date
HK1206608A1 true HK1206608A1 (zh) 2016-01-15

Family

ID=47143719

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107168.4A HK1206608A1 (zh) 2012-11-07 2015-07-27 三唑並化合物

Country Status (12)

Country Link
US (1) US9617271B2 (zh)
EP (1) EP2916842B1 (zh)
JP (1) JP6293161B2 (zh)
KR (1) KR20150081354A (zh)
CN (1) CN104768554B (zh)
BR (1) BR112015009649A2 (zh)
CA (1) CA2888324A1 (zh)
ES (1) ES2603931T3 (zh)
HK (1) HK1206608A1 (zh)
MX (1) MX2015005375A (zh)
RU (1) RU2015118286A (zh)
WO (1) WO2014072261A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3099690B1 (en) * 2014-01-31 2019-08-28 F.Hoffmann-La Roche Ag (hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders
CN104086553B (zh) * 2014-06-13 2016-04-27 南京药石科技股份有限公司 一种制备7-溴咪唑并[2,1-f][1,2,4]三嗪-4-胺的方法
TW201639851A (zh) * 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 雙環咪唑衍生物
US10112944B2 (en) * 2015-03-18 2018-10-30 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of TNF
AU2016233289A1 (en) * 2015-03-18 2017-11-09 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of TNF
KR20190110106A (ko) * 2017-01-06 2019-09-27 더 존스 홉킨스 유니버시티 신경퇴행성 질환의 치료를 위한 중성 스핑고미엘리나제 2(nSMAse2)의 저분자 억제제
KR102628073B1 (ko) 2017-01-10 2024-01-22 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
WO2020072964A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
TW202031250A (zh) 2018-11-06 2020-09-01 丹麥商Ｈ 朗德貝克公司 用於治療負性症狀和認知損傷之pde10a抑制劑
BR112020013697A2 (pt) 2018-11-06 2020-12-01 H. Lundbeck A/S compostos para tratamento de sintomas negativos e comprometimentos cognitivos
WO2020103939A1 (zh) * 2018-11-22 2020-05-28 上海科技大学 三唑并环类化合物、其制备方法、中间体和应用
KR20210116488A (ko) 2018-12-20 2021-09-27 인사이트 코포레이션 액티빈 수용체-유사 키나제-2의 억제제로서의 이미다조피리다진 및 이미다조피리딘 화합물
WO2021216951A1 (en) 2020-04-24 2021-10-28 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
WO2021216949A1 (en) 2020-04-24 2021-10-28 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004559A2 (en) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
CA2575430A1 (en) * 2004-08-03 2006-02-16 Merck & Co., Inc. 1,3-disubstituted heteroaryl nmda/nr2b antagonists
WO2006128693A2 (en) 2005-06-01 2006-12-07 Ucb Pharma, S.A. 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
US8501738B2 (en) * 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
CN102791715B (zh) 2009-12-31 2016-04-27 卡洛斯三世国家癌症研究中心基金会 用作激酶抑制剂的三环化合物
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
WO2012147890A1 (ja) * 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
WO2013178569A1 (en) * 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Pyrrolidino heterocycles
AU2013269800A1 (en) * 2012-05-30 2014-10-09 F. Hoffmann-La Roche Ag Triazolo compounds as PDE10 inhibitors

Also Published As

Publication number Publication date
WO2014072261A1 (en) 2014-05-15
BR112015009649A2 (pt) 2017-07-04
CA2888324A1 (en) 2014-05-15
RU2015118286A (ru) 2016-12-27
EP2916842B1 (en) 2016-10-19
CN104768554B (zh) 2018-04-17
US20150232472A1 (en) 2015-08-20
JP2015536959A (ja) 2015-12-24
CN104768554A (zh) 2015-07-08
ES2603931T3 (es) 2017-03-02
MX2015005375A (es) 2015-07-21
US9617271B2 (en) 2017-04-11
EP2916842A1 (en) 2015-09-16
KR20150081354A (ko) 2015-07-13
JP6293161B2 (ja) 2018-03-14

Similar Documents

Publication Publication Date Title
HK1206608A1 (zh) 三唑並化合物
SG10201604661QA (en) A Container
PL2870072T3 (pl) Dozownik leków
EP2828177A4 (en) DISTRIBUTOR
HK1211524A1 (zh) 用於藥物的分配器
AU344810S (en) A beverage dispenser
GB201323133D0 (en) Tablet dispenser
EP2670461A4 (en) PATIENT-CONTROLLED ADMINISTRATION OF AEROSOLS
GB201414334D0 (en) Auto-refill single dose dispenser
IL235131A0 (en) dispenses medicine
AU347052S (en) A container
EP2866626A4 (en) DISTRIBUTOR
GB201122245D0 (en) A pharmaceutical package
ZA201501897B (en) A pharmaceutical composition
GB2504151B (en) A container
HK1206656A1 (zh) 用於藥物輸送裝置的組合體
AP2015008470A0 (en) Dispenser
AP00457S1 (en) Dispenser
IL220794A (en) Medication dispenser
GB2482211B (en) A dispensing system
GB201214835D0 (en) A container
ZA201407460B (en) A dispenser
GB201221372D0 (en) A dispenser
IL223727A0 (en) Dispenses time-guided pills
GB201208634D0 (en) A dispensing arrangement

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20221028